Coralen [inj.] en es it fr

Coralen [inj.] Brand names, Coralen [inj.] Analogs

Coralen [inj.] Brand Names Mixture

  • Tritec (ranitidine bismuth citrate salt)

Coralen [inj.] Chemical_Formula


Coralen [inj.] RX_link

Coralen [inj.] fda sheet

Coralen_[inj.] FDA

Coralen [inj.] msds (material safety sheet)

Coralen_[inj.] MSDS

Coralen [inj.] Synthesis Reference

B. J. Price et al., U.S. Pat. 4,128,658 (1978)

Coralen [inj.] Molecular Weight

314.405 g/mol

Coralen [inj.] Melting Point

69-70 oC

Coralen [inj.] H2O Solubility

24.7 mg/mL

Coralen [inj.] State


Coralen [inj.] LogP


Coralen [inj.] Dosage Forms

Capsule; Liquid; Solution; Tablet; Syrup

Coralen [inj.] Indication

Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).

Coralen [inj.] Pharmacology

Ranitidine is a histamine H2-receptor antagonist similar to cimetidine and famotidine. An H2-receptor antagonist, often shortened to H2 antagonist, is a drug used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells. These drugs are used in the treatment of dyspepsia, however their use has waned since the advent of the more effective proton pump inhibitors. Like the H1-antihistamines, the H2 antagonists are inverse agonists rather than true receptor antagonists.

Coralen [inj.] Absorption

Approximately 50% bioavailability orally.

Coralen [inj.] side effects and Toxicity

LD50=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.

Coralen [inj.] Patient Information


Phenylketonurics: ZANTAC 25 EFFERdose Tablets contain phenylalanine 2.81 mg per 25 mg of ranitidine. ZANTAC 150 EFFERdose Tablets
contain phenylalanine 16.84 mg per 150 mg of ranitidine. ZANTAC EFFERdose Tablets should not be chewed, swallowed whole, or dissolved
on the tongue.

Coralen [inj.] Organisms Affected

Humans and other mammals